Study Finds Low Risk of Secondary Cancers After CAR-T Cell Therapy

Research involving over 700 patients suggests CAR-T cell therapy is safer than previously thought, with secondary cancer risks comparable to other treatments.

• FDA's 2023 warning about secondary cancers in CAR-T therapy prompted this study.
• Stanford Medicine's research indicates a 6.5% risk of secondary cancers within three years.
• The study found no evidence that engineered CAR-T cells caused secondary cancers.
• Secondary cancers may arise due to pre-existing conditions or immunosuppression from treatment.
• Findings emphasize the importance of monitoring and screening patients undergoing CAR-T therapy.

3 Articles

ScienceDaily Live Science UPI